Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | PPIA | P62937 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 5/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9742662 | 0.94 | P2RX7 (0.39) | FOLH1MEN1KMT2AGAAMAPK1 | |
| SCHEMBL9742297 | 0.92 | P2RX7 (0.41) | FOLH1MEN1KMT2AGAAMAPK1 | |
| SCHEMBL7272144 | 0.92 | P2RX7 (0.41) | FOLH1MEN1KMT2AGAAMAPK1 | |
| SCHEMBL5538732 | 0.90 | CTSL (0.34) | FOLH1MEN1KMT2AGAAMAPK1 | |
| SCHEMBL27594406 | 0.89 | MEN1 (0.36) | FOLH1MEN1KMT2AGAAMAPK1 | |
| SCHEMBL9743498 | 0.87 | CTSK (0.34) | FOLH1MEN1KMT2AGAAMAPK1 | |
| SCHEMBL31059483 | 0.87 | MEN1 (0.35) | MEN1KMT2AGAAMAPK1CTSL | |
| SCHEMBL9744392 | 0.83 | P2RX7 (0.40) | FOLH1MEN1KMT2AGAAMAPK1 | |
| SCHEMBL15297512 | 0.83 | MEN1 (0.37) | MEN1KMT2AGAAMAPK1CTSL | |
| SCHEMBL3369497 | 0.83 | TDP1 (0.42) | MEN1KMT2AGAAMAPK1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317777-A1 | NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2024178335-A2 | NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| WO-2020243178-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317777-A1 | NOVEL MACROCYCLIC AMINOPYRAZOLE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK20, CDK3 | FOLH1 3962/4885MEN1 1719/4885KMT2A 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.